Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
Weisser
M
M
Schmid
C
C
Schoch
C
C
Hiddemann
W
W
Kolb
H J
HJ
D000328:Adult; D000368:Aged; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate